Semaglutide for Weight Loss: Complete Patient Guide
Everything you need to know about semaglutide — how it works, what clinical trials show, who qualifies, and how to access physician-supervised treatment.
· DietsMD Editorial Team · 14 min read
Medically reviewed by DietsMD Board-Certified Physicians specializing in obesity medicine and metabolic health. Content is reviewed for clinical accuracy and updated regularly.
Quick Answer
Semaglutide is an FDA-approved GLP-1 receptor agonist for chronic weight management (brand name Wegovy®). In the STEP-1 clinical trial, patients lost an average of 14.9% of body weight over 68 weeks. It is administered as a once-weekly subcutaneous injection and requires a physician prescription.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medications that mimic a hormone naturally produced in the gut after eating. It was originally developed by Novo Nordisk for type 2 diabetes management under the brand name Ozempic®.
At a higher dose formulation (2.4 mg weekly), semaglutide received FDA approval in June 2021 as Wegovy® for chronic weight management in adults with obesity or overweight with at least one weight-related health condition.
How Semaglutide Works for Weight Loss
Appetite Suppression
Semaglutide acts on GLP-1 receptors in the hypothalamus, reducing hunger signals and helping patients feel full sooner and remain satisfied longer between meals.
Slowed Gastric Emptying
Semaglutide slows the rate at which food moves from the stomach into the small intestine, prolonging fullness and reducing glucose absorption speed.
Blood Sugar Regulation
Semaglutide stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner, reducing post-meal blood sugar spikes without causing hypoglycemia in non-diabetic patients.
Reduced Reward-Driven Eating
Emerging research suggests semaglutide may act on brain reward pathways, reducing the appeal of high-calorie foods and compulsive eating behaviors.
Semaglutide Clinical Trial Results
STEP-1 Trial
- Participants: 1,961 adults with obesity or overweight with a weight-related condition, without type 2 diabetes
- Duration: 68 weeks
- Result: Average weight loss of 14.9% vs. 2.4% with placebo
- 68% of participants lost ≥10% of body weight; 50% lost ≥15%
SELECT Trial (Cardiovascular Outcomes)
- Participants: 17,604 adults with obesity and established cardiovascular disease
- Result: Semaglutide reduced MACE by 20% vs. placebo — first weight loss medication to receive this FDA indication
Semaglutide Dosing and Administration
| Week | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg/week | Initiation — tolerance building |
| Weeks 5–8 | 0.5 mg/week | Dose escalation |
| Weeks 9–12 | 1.0 mg/week | Dose escalation |
| Weeks 13–16 | 1.7 mg/week | Dose escalation |
| Week 17+ | 2.4 mg/week | Maintenance dose (target) |
Potential Benefits of Semaglutide
- Significant, sustained weight loss averaging ~15% of body weight in clinical trials
- Reduced cardiovascular risk (SELECT trial)
- Improved blood sugar control and reduced HbA1c
- Lower blood pressure and improved lipid profiles
- Reduced appetite and food cravings
- Once-weekly dosing for convenience
Side Effects and Safety
Common Side Effects
- Nausea — most common, especially in the first weeks
- Vomiting, diarrhea, constipation, abdominal discomfort
- Fatigue, injection site reactions
Serious Risks (Rare)
- Thyroid C-cell tumors: Boxed warning for patients with history of MTC or MEN2
- Pancreatitis: Rare; discuss history with physician
- Gallbladder disease: Rapid weight loss can increase gallstone risk
Who Qualifies for Semaglutide?
- BMI of 30 or greater (obesity), OR
- BMI of 27 or greater with at least one weight-related condition
- No personal or family history of MTC or MEN2
- Not pregnant or planning to become pregnant
Find Out If Semaglutide Is Right for You
DietsMD board-certified physicians evaluate your health history and prescribe semaglutide when clinically appropriate. Discreet home delivery. Ongoing physician support.
How to Get Semaglutide Online
- Complete a medical intake form. Provide your health history, medications, weight history, and goals.
- Physician consultation. A board-certified physician reviews your intake and determines whether semaglutide is appropriate.
- Prescription issued. Sent to a licensed U.S. pharmacy.
- Discreet home delivery. Shipped directly to your home.
- Ongoing monitoring. Regular physician check-ins throughout treatment.
Brand-Name vs. Compounded Semaglutide
- Brand-name Wegovy®: FDA-approved, manufactured by Novo Nordisk. May be covered by some insurance plans.
- Compounded semaglutide: Prepared by licensed U.S. compounding pharmacies (503A or 503B). Legal when prescribed by a licensed physician. Always confirm accreditation.
Semaglutide vs. Tirzepatide: Which Is Right for You?
Both semaglutide and tirzepatide are FDA-approved GLP-1 medications for weight loss. Tirzepatide has demonstrated greater average weight loss (~20–22% vs ~15%), but semaglutide has a longer track record and established cardiovascular benefit data from the SELECT trial.
Read our full GLP-1 weight loss guide or explore top online medical weight loss programs to learn more.
Frequently Asked Questions About Semaglutide
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management (Ozempic) and chronic weight management (Wegovy). It is also FDA-approved for reducing cardiovascular risk in patients with obesity and established cardiovascular disease.
In the STEP-1 trial, participants lost an average of 14.9% of body weight over 68 weeks. 68% lost 10% or more, and 50% lost 15% or more. Individual results vary.
Most patients notice appetite suppression within 2 to 4 weeks. Measurable weight loss typically begins within 4 to 8 weeks. Maximum weight loss in trials was at 68 weeks.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.
Clinical data shows patients typically regain significant weight within 12 months of stopping. Many physicians recommend ongoing treatment as part of a long-term strategy.
Yes. Licensed telehealth platforms like DietsMD allow patients to consult with physicians online, receive a prescription, and have medication delivered home. A physician evaluation is required.
Coverage varies by plan. Some commercial plans cover Wegovy. Medicare currently does not cover weight loss medications.
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnant patients should not use semaglutide.
Tirzepatide has demonstrated greater average weight loss (~20-22% vs ~15%). Semaglutide has a longer track record and established cardiovascular benefit data from the SELECT trial.
